Immunotherapies based on monoclonal antibodies that block the PD-1/PD-L1 interaction have transformed the treatment of certain cancers such as melanoma and non-small-cell lung cancer but yielded less favorable outcomes for other cancers, including cancers of the breast, colon, and pancreas [8]. Here, CD274 is linked to cancer.